MedicalResearch.com Interview with:
Dr. Ming Yang
Key Laboratory of Microsystems and Microstructures Manufacturing,
Harbin Institute of Technology,
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Self-healing materials and coatings are smart solutions to environmental and energy problems. There are heavy demands for these materials in many productions such as consumer electronics, the automotive industry and healthcare.
Current coatings that can self-heal are typically soft. This means they are not as anti-scratch as rigid surfaces and the benefit of the ability to repair themselves could be overwhelmed by their limited robustness vulnerable to normal mechanical contact. It would be very useful to have a self-healing coating with a hardness that can be comparable or even outperform rigid coatings. This is normally difficult because mechanical hardness and self-healing are two conflicting properties with the opposite dependence on polymer dynamics. One good example in this context is many soft tissues can self-heal, but a notable exception is tooth enamel, which is the hardest part in our body but has no way to recover after decay. A new design will be needed to circumvent the fundamental limitation.
We find that by mimicking the structure of epidermis, it is possible to combine two contradictory properties into an artificial coating, namely, self-healing ability and high hardness. The success relies on the placement of a hard layer containing graphene oxide on top of a soft sublayer with a seamless interface for interlayer diffusion. This allows a similar healing mechanism as that in skin, but the coating is not soft and has a hardness that even approaches tooth enamel. Continue reading
Lee Buckler, CEO
RepliCel Life Sciences
MedicalResearch.com: What is the background for this your company, RepliCel.com?
Response: RepliCel Life Sciences is a Canadian regenerative medicine company based in Vancouver, British Columbia that was founded in 2006. The company focuses on the development of cell therapies using a patient’s own cells (autologous cell therapy). It is developing treatments targeted at healing chronic tendon injuries that have failed to heal properly, hair restoration, and the treatment of damaged and aged skin.
MedicalResearch.com eInterview with Dr. Giuseppe Orlando, M.D., Ph.D.
Instructor, General Surgery
Specialty Areas: Transplant Urology, Kidney Transplantation, Pancreas Transplantation, Transplant Immunology, Transplant Immunosuppression, Transplant Surgery
Wake Forest Baptist Medical Center
Medical Center Boulevard, Winston-Salem, NC 27157.
MedicalResearch.com: What are the main findings of the study?
Dr. Orlando: Our study shows that we can use discarded kidneys from deceased human donors as platform for kidney regeneration investigations. As of now, we are using porcine models, after having developed smaller scale models (mainly in rodents, as it normally occurs in health science ie we need to provide the proof of concept in small animals before scaling up to larger animals which, for obvious reasons, are clinically more relevant). In regenerative medicine we know that cells do not survive if they are not seeded on supporting platforms which we call “scaffolds”. There are several types of scaffolds, but probably the most effective are the ones that we can produce from animal/human organs. Basically, every organ consists of a cellular component which is endowed within the framework of the so-called extracellular matrix. When we strip cells out of an organ, what remains is the acellular extracellular matrix. Quite strikingly, the acellular organ in question maintains the same shape and volume that it had before stripping. What counts is that the so-obtained scaffold contains most information that cells require to grow, be viable and exert their function. It looks like this happens also for discarded human kidneys which may represent the most promising platform for our research